LabCorp Commences Offer for Orchid Shares | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Laboratory Corporation of America today said that it has launched its cash tender offer to acquire all of the outstanding common shares of Orchid Cellmark.

The firms signed the merger agreement earlier this month, under which LabCorp will pay $2.80 per share to acquire all outstanding shares of Orchid including options. The total value of the deal is around $85.4 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.